Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease
Open Access
- 29 March 2021
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 394 (4) , 751-761
Abstract
Glomeruli and renal tubule injury in chronic kidney disease (CKD) is reported to involve induction of macrophage activation through the CCL2/CCR2 axis. The effects of inhibitors of the CCL2/CCR2 axis, such as anti-CCL2 antibody and CCR2 antagonist, on kidney function in animal models or humans with kidney dysfunction have been demonstrated. The N-terminal glutamine on immature CCL2 is replaced with pyroglutamate (pE) by glutaminyl cyclase (QC) and isoQC. pE-CCL2 is stable and resistant to peptidases. We hypothesized that inhibiting QC/isoQC activity would lead to the degradation of CCL2, thereby ameliorating CKD and reducing kidney inflammation. To test this hypothesis, we investigated the renoprotective properties of the QC/isoQC inhibitor PQ529 in anti-glomerular basement membrane (GBM) antibody–induced glomerulonephritis Wistar Kyoto (WKY) rats. Three-week repeated administration of PQ529 (30 and 100 mg/kg, twice daily) significantly reduced the serum and urine CCL2 and urinary protein excretion in a dose-dependent manner. Correlations between the urinary protein level and serum or urinary CCL2 levels were confirmed in tested animals. Repeated administration of PQ529 significantly reduced the expression of CD68, a macrophage marker, in the kidney cortex and mononuclear infiltration into the tubulointerstitium. In addition, decreased levels of urinary KIM-1, β2 microglobulin, and clusterin were detected, suggesting the inhibition of inflammation in both the proximal and distal tubules. These results suggest that PQ529 suppresses the progression of inflammation-induced renal dysfunction by inhibiting the CCL2/CCR2 axis. Inhibition of QC/isoQC may thus be a viable alternative therapeutic approach for treating glomerulonephritis and CKD patients.Keywords
This publication has 40 references indexed in Scilit:
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survivalDrug Discovery Today, 2012
- Tubulointerstitial injury and the progression of chronic kidney diseasePediatric Nephrology, 2011
- Novel approach to inhibiting chemokine functionEMBO Molecular Medicine, 2011
- The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditionsEMBO Molecular Medicine, 2011
- An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetesKidney International, 2011
- CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic miceKidney International, 2010
- Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectivesPharmacology & Therapeutics, 2010
- Review: Renal protection by inhibition of the renin-angiotensin-aldosterone systemJournal of the Renin-Angiotensin-Aldosterone System, 2009
- Isolation of an Isoenzyme of Human Glutaminyl Cyclase: Retention in the Golgi Complex Suggests Involvement in the Protein Maturation MachineryJournal of Molecular Biology, 2008
- Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitusClinical and Experimental Nephrology, 2006